Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 14/20 | 0.92 |
| ▸ | ARG2 | P78540 | 14/20 | 0.92 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006144 | 1.00 | ARG1 (0.92) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL10006186 | 0.98 | ARG1 (0.92) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL29657628 | 0.98 | ARG1 (0.92) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL30169876 | 0.96 | ARG1 (1.00) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL895005 | 0.96 | ARG1 (1.00) | ARG1ARG2HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL894310 | 0.94 | ARG1 (0.98) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL14879593 | 0.93 | ARG1 (0.90) | ARG1ARG2 | |
| SCHEMBL30169898 | 0.93 | ARG1 (0.90) | ARG1ARG2 | |
| SCHEMBL18079434 | 0.91 | ARG1 (0.77) | ARG1ARG2HTR1ADRD2HTR2A | |
| SCHEMBL18079443 | 0.89 | ARG1 (0.77) | ARG1ARG2HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-110123820-B | Arginase inhibitors and methods of use thereof | 阿斯利康公司 | 2022-05-31 | — | — | CN | disclosed |